Abstract
Semaglutide 2.4 mg is an injectable glucagon-like peptide-1 receptor agonist used for chronic weight management. There is limited published evidence on characteristics of patients treated with semaglutide 2.4 mg in a real-world setting. Our objective was to characterize US patients with obesity initiating semaglutide 2.4 mg compared with patients treated with other branded antiobesity medications (bAOMs) or without bAOM treatment using linked claims and electronic medical record databases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
